Skip to main content

Published locations for FDA to review dupilumab for treating chronic spontaneous urticaria

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA to review dupilumab for treating chronic spontaneous urticaria

User login

  • Reset your password
  • /content/fda-review-dupilumab-treating-chronic-spontaneous-urticaria
  • /clinicianreviews/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic
  • /edermatologynews/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic
  • /familypracticenews/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic
  • /fedprac/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic-spontaneous
  • /internalmedicinenews/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic
  • /pediatricnews/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic-spontaneous
  • /pediatrics/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic-spontaneous
  • /internalmedicine/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic
  • /dermatology/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic-spontaneous
  • /familymedicine/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic-spontaneous